Aryastha Life Sciences is proud to advance transformative, personalized oncology solutions that match patients with approved therapies and identify promising experimental treatment options using patient derived cancer cells and next generation tumor organoids. Our translational research platform is specifically engineered to bring cutting edge, individualized cancer testing into routine clinical practice-making precision oncology more accessible and affordable for clinicians and patients alike.
This platform has undergone rigorous validation through longitudinal clinical outcomes, underscoring its potential to guide more effective and personalized treatment decisions. Our scientific findings were presented by our Chief Clinical Advisor, Dr. Gnaneswar Atturu, at the SITC2025 Annual Meeting in National Harbor, Maryland, and will be featured at the AACR2026 Annual Meeting in San Diego.
